CompletedPhase 4NCT00522821
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
Studying Recurrent infections associated with rare immunoglobulin isotypes deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Prothya Biosolutions
- Principal Investigator
- J T van Dissel, PhD, MDLUMC
- Intervention
- intravenous immunoglobulins(drug)
- Enrollment
- 55 target
- Eligibility
- 5 years · All sexes
- Timeline
- 2007 – 2014
Study locations (9)
- Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands
- AMC, Amsterdam, Netherlands
- VU, Amsterdam, Netherlands
- UMCG, Groningen, Netherlands
- LUMC, Leiden, Netherlands
- AZM, Maastricht, Netherlands
- UMC St Radboud, Nijmegen, Netherlands
- Erasmus MC, Rotterdam, Netherlands
- UMCU, Utrecht, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00522821 on ClinicalTrials.gov